Allergan BOD rejects latest Valeant offer

Unsurprisingly, Allergan's (AGN) BOD rejects Valeant Pharmaceuticals' (VRX) latest offer of 0.83 shares of Valeant common stock plus $72 in cash for each share of AGN common stating that its offer substantially undervalues Allergan. It also cites the large component of VRX stock in the proposal. The Board believes its value is uncertain due to its perception of the lack of sustainability of VRX's business model.

Pershing Square believes it has the shareholder votes to override the Board's decision and accept the proposal.

From other sites
Comments (1)
  • thodoris91
    , contributor
    Comments (61) | Send Message
    good for them
    10 Jun 2014, 01:34 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs